Development of novel alkylating drugs targeting oncogenic drivers
| Project/Area Number |
17H03602
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Chiba Cancer Center (Research Institute) |
|---|
Principal Investigator |
Nagase Hiroki 千葉県がんセンター(研究所), がん遺伝創薬研究室, 研究所長 (90322073)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2019: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2017: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Keywords | 分子標的治療 / ゲノムDNA / 個別化治療 / 早期がん血液診断 / DNA副溝結合化合物 / アルキル化剤 / ゲノム創薬 / 効果副作用予測 / 腫瘍集積性 / がん関連遺伝子 / DNA結合化合物 / がん / がんドライバー変異 / ピロールイミダゾールポリアミド / 創薬開発 / 標的探索 / がん遺伝子 / ゲノム / トランスレーショナルリサーチ |
|---|
| Outline of Final Research Achievements |
Using our state-of-art drug development technology many anti-cancer drug candidates have been synthesized and found anti-cancer effect in animal models. Since unexpected side-effect is a major problem of drug development, an algorism to predict side-effects has been developed by using machine learning techniques. Predicted side effect has been confirmed using mouse models of human cancer after drug candidate administration. We believe our technology should allow us to develop new anti-cancer drugs for precision medicine. In addition DNA binding molecules can be used for early diagnosis and new blood test to diagnose cancer even in early stage has been identified.
|
| Academic Significance and Societal Importance of the Research Achievements |
今までの低分子薬剤は蛋白質やRNAを標的にするものが主で、直接細胞のゲノムDNAを配列特異的に標的にする化合物をデザイン・合成する技術はあまり注目されていませんでした。本課題では新たなゲノムDNAを標的にする手法で副作用を予測した上で抗癌治療薬を開発できる可能性を示すことが出来、加えて同技術の応用でがんの早期診断が可能になる技術も開発でき学術的な意義及び社会的意義は大きかったと考えます。さらに本技術はコロナウィルス感染治療にも応用できる可能性があり、感染症専門家との共同研究にも着手できました。
|
Report
(4 results)
Research Products
(57 results)
-
-
[Journal Article] Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment.2019
Author(s)
Kitagawa Y, Okumura K, Watanabe T, Tsukamoto K, Kitano S, Nankinzan R, Suzuki T, Hara T, Soda H, Denda T, Yamaguchi T, Nagase H.
-
Journal Title
Scientific Reports
Volume: 9
Pages: 11346-11346
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] orced expression of NR4A3 induced differentiation of human neuroblastoma-derived NB1 cells.2019
Author(s)
Hirano H, Nagasaki-Maeoka E, Ishizuka Y, Takatori A, Watanabe Y, Hoshi R, Yoshizawa S, Kawashima H, Uekusa S, Sugito K, Uehara S, Fukuda N, Nagase H, Takayama T, Soma M, Koshinaga T and Fujiwara K.
-
Journal Title
Medical Oncology
Volume: 36
Pages: 66-66
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Estimating genome-wide off-target effects for pyrrole-imoidazole polyamide binding by a pathway-based expression profiling approach2019
Author(s)
J, Lin, S, Krishnamurthy, H. Yoda, Y. Shinozaki, T. Watanabe, N. Koshikawa, A. Takatori, P. Horton, H. Nagase
-
Journal Title
PLOS ONE
Volume: 14
Pages: 4-4
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
[Journal Article] Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis2018
Author(s)
Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J
-
Journal Title
Oncotarget.
Volume: 8
Pages: 107513-107529
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
